睿知中国疾病研究地图
候选清单0

即将招募多发性骨髓瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07114432,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Must meet the definition of genetic high-risk MM as per the "2024 Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma", defined as having one or more of the following high-risk cytogenetic abnormalities (HRCA) confirmed by FISH or mitotic karyotype analysis:

    入选标准第 5 条

  3. History of Class III or IV heart failure as defined by the New York Heart Association (NYHA), unstable angina, myocardial infarction within the last 6 months, or sustained (>30 seconds) ventricular arrhythmia.

    排除标准第 13 条

  4. Has not received more than 4 cycles of induction therapy at the time of enrollment.

    入选标准第 12 条

    Has undergone major surgery within 14 days prior to the first dose of the study drug.

    排除标准第 21 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at enrollment.

    入选标准第 8 条

    ECOG performance status of 0-2.

    入选标准第 29 条

  6. Total serum bilirubin < 2 times the upper limit of normal (ULN).

    入选标准第 23 条

    Serum creatinine < ULN.

    入选标准第 24 条

    Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 3 times ULN.

    入选标准第 25 条

    Estimated or calculated creatinine clearance (CrCl) ≥ 40 mL/min, via CKD-EPI or Cockcroft-Gault formula.

    入选标准第 26 条

  7. Human Immunodeficiency Virus (HIV) infection (subjects must have a negative HIV 1/2 antibody screen).

    排除标准第 7 条

    Hepatitis C Virus (HCV) infection (subjects must have a negative anti-HCV antibody screen).

    排除标准第 8 条

    Hepatitis B Virus (HBV) infection (subjects must have a negative HBsAg screen).

    排除标准第 9 条

  8. Is pregnant, breastfeeding, or, for female subjects, is planning a pregnancy within 6 months.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07114432,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. A subject will be eligible for this trial only if all of the following criteria are met:
  2. Is willing and able to provide a written informed consent form before any trial-related activities are performed.
  3. Must have a diagnosis of Multiple Myeloma (MM) according to the World Health Organization (WHO) 2017 revised criteria.
  4. Must be diagnosed with active MM according to the International Multiple Myeloma Working Group (IMWG) criteria.
  5. Must meet the definition of genetic high-risk MM as per the "2024 Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma", defined as having one or more of the following high-risk cytogenetic abnormalities (HRCA) confirmed by FISH or mitotic karyotype analysis:
  6. Must have a documented MM type that is B-cell maturation antigen (BCMA) positive and/or CD19 positive, confirmed at screening or from prior medical records.
  7. Age ≥ 18 years, male or female.
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at enrollment.
  9. Has a life expectancy of ≥ 12 weeks.
  10. Meets the following prior therapy requirements:
  11. Is currently receiving or has received an induction therapy regimen containing at least a proteasome inhibitor, an immunomodulatory agent, or a monoclonal antibody as a backbone therapy.
  12. Has not received more than 4 cycles of induction therapy at the time of enrollment.
  13. Has had an effective response to induction therapy without evidence of disease progression per IMWG criteria.
  14. Prior radiotherapy is permitted before enrollment.
  15. Is scheduled to initiate maintenance and/or consolidation therapy 3 months after cell reinfusion, following successful enrollment.
  16. Must have measurable disease to assess Progression-Free Survival (PFS). Measurable disease is defined by at least one of the following criteria:
  17. Serum M-protein (M-spike) ≥ 0.5 g/dL.
  18. 24-hour urine M-protein (M-spike) ≥ 200 mg.
  19. Abnormal serum free light chain (FLC) ratio with an involved FLC level ≥ 50 mg/L.
  20. For IgA MM: total serum IgA level outside the normal range.
  21. Note: The presence of measurable disease is not required at enrollment; it can be determined from historical lab data. For instance, a subject who achieved a complete response after induction and has no measurable disease at enrollment is still eligible if they met any of the above criteria after their initial diagnosis.
  22. Adequate organ function as defined by the following laboratory values:
  23. Total serum bilirubin < 2 times the upper limit of normal (ULN).
  24. Serum creatinine < ULN.
  25. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 3 times ULN.
  26. Estimated or calculated creatinine clearance (CrCl) ≥ 40 mL/min, via CKD-EPI or Cockcroft-Gault formula.
  27. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% of predicted value (corrected or uncorrected for anemia/alveolar volume).
  28. Adequate bone marrow function defined as: Absolute neutrophil count ≥ 0.5×10⁹/L and platelet count ≥ 20×10⁹/L.
  29. ECOG performance status of 0-2.
  30. Left ventricular ejection fraction (LVEF) ≥ 50% with no pericardial effusion.
  31. Must have recovered to ≤ Grade 1 (per CTCAE) from any Serious Adverse Event (SAE) before enrollment.
  32. Able to comply with the study visit schedule and other protocol requirements.

排除标准:Exclusion Criteria:

  1. A subject will not be eligible for this trial if any of the following criteria are met:
  2. Known history of allergic reaction, hypersensitivity, intolerance, or contraindication to the BCMA/CD19 allogeneic CAR-T product or any of its excipients, including fludarabine, cyclophosphamide, and tocilizumab.
  3. Diagnosis of plasma cell leukemia.
  4. Presence of non-paraskeletal extramedullary disease.
  5. Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with active graft-versus-host disease (GVHD) that requires treatment with steroids or immunosuppressive agents.
  6. Presence of a severe, active infection, including:
  7. Human Immunodeficiency Virus (HIV) infection (subjects must have a negative HIV 1/2 antibody screen).
  8. Hepatitis C Virus (HCV) infection (subjects must have a negative anti-HCV antibody screen).
  9. Hepatitis B Virus (HBV) infection (subjects must have a negative HBsAg screen).
  10. History of prior gene therapy or genetically modified cell immunotherapy.
  11. Active autoimmune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis; or a history of a severe autoimmune disease (as judged by the Principal Investigator) that required long-term immunosuppressive therapy.
  12. Diagnosis of an acquired or congenital immunodeficiency disease.
  13. History of Class III or IV heart failure as defined by the New York Heart Association (NYHA), unstable angina, myocardial infarction within the last 6 months, or sustained (>30 seconds) ventricular arrhythmia.
  14. History of seizure disorder or other central nervous system (CNS) disease; history or current evidence of CNS involvement with MM. Note: CNS screening (e.g., lumbar puncture) is not mandatory unless symptoms are present.
  15. History of other primary malignancies, except for the following:
  16. Non-melanoma skin cancer (e.g., basal cell carcinoma) cured by resection.
  17. Carcinoma in situ (e.g., cervical, bladder, or breast cancer) that has been cured.
  18. Is pregnant, breastfeeding, or, for female subjects, is planning a pregnancy within 6 months.
  19. Participation in another clinical trial within the last month.
  20. Any condition which, in the opinion of the investigator, would place the subject at increased risk or interfere with the trial results.
  21. Has undergone major surgery within 14 days prior to the first dose of the study drug.

引自 ClinicalTrials.gov, NCT07114432, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07114432,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07114432